Skip to main content
. Author manuscript; available in PMC: 2016 Sep 21.
Published in final edited form as: S Afr Med J. 2015 Sep 21;105(8):642–647. doi: 10.7196/samjnew.8794

Table 4.

Treatment, chronic respiratory disease group

Medications prescribed All participants
(N=1 157)
n (%)		 SGRQ symptom
domain score
Median (IQR)		 SGRQ activity
domain score
Median (IQR)
No chronic respiratory disease medications 567 (49.0) 52.6 (29.8 – 68.5) 67.2 (47.7 – 85.8)
Selective β2-agonist 558 (48.2) 64.6 (44.9 – 78.9) 79.8 (59.5 – 92.5)
Inhaled corticosteroids (any dose) 388 (33.5) 64.6 (42.8 – 79.3) 80.3 (60.3 – 92.5)
Inhaled corticosteroid (≥800 µg/d) 346 (29.9) 64.9 (41.8 – 80.2) 80.4 (60.3 – 92.5)
Theophylline 121 (10.5) 70.4 (51.8 – 83.0) 79.8 (60.4 – 92.5)
Ipratropium bromide 91 (7.9) 69.7 (52.2 – 81.6) 85.8 (60.4 – 93.2)